-
Mosunetuzumab, sold
under the
brand name Lunsumio, is a
monoclonal antibody used for the
treatment of
follicular lymphoma. It
bispecifically binds CD20...
- in July 2023.
Bispecifically binds CD20 and CD3 to
engage T-cells.
Mosunetuzumab was
approved for
medical use in the
European Union in June 2022. Solitomab...
-
Loncastuximab tesirine L01FX23
Tisotumab vedotin L01FX24
Teclistamab L01FX25
Mosunetuzumab L01FX26
Mirvetuximab soravtansine L01FX27
Epcoritamab L01FX28 Glofitamab...
-
tisagenlecleucel (Kymriah) treatment. Cell
therapy Checkpoint inhibitor Glofitamab Mosunetuzumab Epcoritamab Gene
therapy Immune checkpoint Fox M (July 12, 2017). "New...
- 2020.
Retrieved 23
January 2020. "FDA
grants accelerated approval to
mosunetuzumab-axgb". U.S. Food and Drug Administration. 22
December 2022. Archived...
- Leukemia/lymphoma lymphoid: CD3 (Glofitamab, Elranatamab,
Mosunetuzumab), CD20 (Glofitamab
Ibritumomab Mosunetuzumab Obinutuzumab Ofatumumab Rituximab Tositumomab)...
- growth; and 7)
Bispecific monoclonal antibody drugs epcoritamab, and
mosunetuzumab. In
preliminary studies on FL
patients who were
known or
thought to...
- FDA: emicizumab, amivantamab, tebentafusp, faricimab, teclistamab,
mosunetuzumab, epcoritamab, glofitamab.
Among the bsAb
programs currently under development...
-
Adagrasib Mirati Therapeutics KRAS G12C-mutated non-small cell lung
cancer Mosunetuzumab Genentech follicular lymphoma Lenacapavir Gilead Sciences HIV-1...
